Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on December 8, 2017. The report details the entry into a material definitive agreement regarding the company's capital raising capabilities.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the increase in the authorized offering size under the At-the-Market (ATM) Issuance Sales Agreement.
- Previous ATM Cap: $40,000,000
- New ATM Cap: $60,000,000
- Commission Rate: 3.0% of gross sales price per share
Material Changes
On December 8, 2017, Cormedix amended its existing At-the-Market Issuance Sales Agreement. The material changes include:
- Sales Agent Change: Replaced MLV & Co. LLC with B. Riley FBR, Inc. as the sales agent (noted as an affiliate of MLV).
- Capacity Increase: Increased the maximum amount of common stock issuable and sellable under the agreement from $40 million to $60 million.
Outlook, Risks, and Management Commentary
Management has authorized the amendment to facilitate future equity sales through B. Riley FBR. The company retains the right to instruct the agent regarding price, time, size limits, and other parameters. The filing notes that B. Riley FBR will use commercially reasonable efforts to sell the stock. No specific guidance, risks, or contingencies beyond the standard terms of the sales agreement were detailed in this summary text.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 (Exhibit 1.1) for specific terms and conditions not summarized here.
- Confirm the impact of the 3.0% commission rate on net proceeds from future ATM sales.
- Review the company's shelf registration statement (Form S-3, File No. 333-203300) to understand the broader context of the offering.
- Check subsequent filings for actual sales volumes executed under the new $60 million cap.